Bortezomib Injection IP 3.5mg
₦49,000.00
Buy Bortezomib Injection 3.5mg Online – Proteasome Inhibitor for Multiple Myeloma and Mantle Cell Lymphoma
Buy Bortezomib Injection IP 3.5mg online from HubPharm Africa, a PCN licensed specialty pharmacy. Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma, given either as a subcutaneous injection or as a rapid intravenous bolus by a trained healthcare professional in a hospital or oncology day unit.
Bortezomib blocks the 26S proteasome, the cell’s protein disposal system. Myeloma cells produce abnormal protein at an extraordinary rate and depend on that disposal system to survive. When it is blocked, damaged proteins accumulate, cell signalling collapses and the malignant cell undergoes apoptosis. Normal cells tolerate the same block far better, which is what gives bortezomib its therapeutic window.
This is a cytotoxic hospital-administered medicine and is never self-injected at home. HubPharm supplies bortezomib against a valid oncologist prescription, with pharmacist verification, controlled handling and documented delivery direct to your treatment centre. We coordinate with your oncology team so each cycle starts on schedule. Same-day delivery within Lagos, 48 hours nationwide, and international shipping available.
Key Features
- First-in-Class Proteasome Inhibitor: A backbone agent in modern myeloma regimens, used in combination with dexamethasone, cyclophosphamide, lenalidomide, thalidomide, melphalan or daratumumab depending on the protocol.
- Subcutaneous or Intravenous: The subcutaneous route gives equivalent efficacy with a markedly lower rate of peripheral neuropathy and is now preferred in most protocols.
- 3.5mg Single-Use Vial: Lyophilised powder for reconstitution, prepared by a pharmacist or trained practitioner immediately before administration.
- Oncology-Grade Handling: Verified prescription, cytotoxic handling standards, tamper-evident packaging and documented chain of custody to your treatment centre.
- Cycle Coordination: Our pharmacists track your treatment calendar and confirm stock ahead of each cycle so therapy is never delayed by supply.
FAQ
What is bortezomib used for?
Bortezomib is used to treat multiple myeloma, both in newly diagnosed patients and in relapsed or refractory disease, and mantle cell lymphoma. It is also used in some protocols for light chain (AL) amyloidosis. It is almost always given as part of a combination regimen rather than alone.
How does bortezomib work?
It reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Proteins that should be degraded accumulate instead, disrupting NF-kB signalling and cell cycle regulation, and triggering programmed cell death in malignant plasma cells.
How is bortezomib given?
By subcutaneous injection into the thigh or abdomen, or as a three to five second intravenous bolus, by a trained healthcare professional. Typical schedules give it on days 1, 4, 8 and 11 of a 21-day cycle, or weekly on days 1, 8, 15 and 22 of a 35-day cycle. Your oncologist selects the schedule.
Can bortezomib be given at home?
No. It must be prepared and administered by trained personnel in a clinical setting, with the dose calculated from body surface area and the route confirmed before each administration.
Why must bortezomib never be given intrathecally?
Intrathecal administration of bortezomib has been fatal. It is for subcutaneous or intravenous use only. Reconstitution concentrations differ between the two routes, which is one reason preparation is restricted to trained staff.
What is the most important side effect to watch for?
Peripheral neuropathy. Tingling, numbness, burning or pain in the hands and feet must be reported at once, because early dose reduction or a switch of schedule usually prevents it becoming permanent. The subcutaneous route substantially reduces this risk.
What other side effects are common?
Fatigue, nausea, diarrhoea or constipation, reduced appetite, fever, low platelet count, anaemia, low white cells, and injection site reactions. Low blood pressure and dizziness on standing can occur, so stand up slowly and keep well hydrated.
Why is an antiviral prescribed with bortezomib?
Bortezomib increases the risk of herpes zoster (shingles) reactivation. Antiviral prophylaxis, usually aciclovir or valaciclovir, is standard practice throughout treatment.
Will my blood be tested during treatment?
Yes. Full blood count is checked before every dose, with particular attention to platelets, which fall predictably during each cycle and recover between cycles. Liver and kidney function and blood glucose are monitored regularly.
Does bortezomib interact with other medicines?
It is metabolised mainly by CYP3A4 and CYP2C19. Strong inducers such as rifampicin and St John’s wort can reduce its effect, and strong inhibitors can increase toxicity. Patients on antidiabetic medicines need closer glucose monitoring. Give your oncology pharmacist a full list of everything you take, including herbal products.
Can bortezomib be used in pregnancy?
No. Bortezomib can harm a developing baby. Effective contraception is required for both men and women during treatment and for a period afterwards as advised by the oncology team. Breastfeeding should be stopped during treatment.
Does the dose need adjusting for liver or kidney problems?
Patients with moderate or severe hepatic impairment start at a reduced dose. Dialysis patients receive bortezomib after the dialysis session, since dialysis can lower drug concentration.
Can I buy bortezomib online in Nigeria?
Yes, on prescription. HubPharm Africa is a PCN licensed pharmacy (LAG20247B39C9) and supplies bortezomib against a valid oncologist prescription, delivered to your treatment centre with documented handling. We deliver same-day within Lagos, within 48 hours nationwide, and ship internationally.
How is bortezomib stored?
Unopened vials are stored below 30°C in the original carton, protected from light. Reconstituted solution should be used promptly and within the timeframe specified in the product leaflet. Preparation and disposal follow cytotoxic handling procedures.
Description
Bortezomib Injection IP 3.5mg – Full Product Information
Active ingredient: Bortezomib 3.5mg, a reversible inhibitor of the 26S proteasome (as bortezomib mannitol boronic ester).
Presentation: Single-use vial of lyophilised powder for solution for injection, for subcutaneous or intravenous administration after reconstitution.
Indications: Multiple myeloma, in newly diagnosed patients as part of combination therapy and in relapsed or refractory disease. Mantle cell lymphoma. Used in some protocols for light chain (AL) amyloidosis.
Legal category: Prescription only cytotoxic medicine. Hospital or specialist oncology use.
How Bortezomib Works
Bortezomib binds reversibly to the chymotrypsin-like site of the 26S proteasome, the multi-enzyme complex that degrades ubiquitinated proteins. Inhibiting it causes accumulation of regulatory proteins, prevents degradation of IkB and therefore blocks NF-kB activation, disrupts cell cycle progression and the unfolded protein response, and induces apoptosis. Malignant plasma cells, which carry an exceptional protein synthesis burden from immunoglobulin production, are disproportionately dependent on proteasome function and therefore disproportionately sensitive.
Administration and Dosage
The usual dose is 1.3mg per square metre of body surface area. A common schedule is days 1, 4, 8 and 11 of a 21-day cycle with a 10-day rest interval, or a weekly schedule on days 1, 8, 15 and 22 of a 35-day cycle. Reconstitution concentration differs by route: 2.5mg/ml for subcutaneous use and 1mg/ml for intravenous use, so the route must be confirmed before preparation. Subcutaneous injection sites in the thigh or abdomen are rotated. Dose is reduced or the schedule modified for peripheral neuropathy, thrombocytopenia, neutropenia and moderate to severe hepatic impairment. Bortezomib must never be administered by the intrathecal route, which has caused death.
Storage and Handling
Store unopened vials below 30°C in the original carton to protect from light. Do not freeze. Reconstituted solution should be used promptly and within the period specified in the manufacturer’s leaflet, protected from light. Preparation, administration and disposal must follow local cytotoxic handling and waste procedures. Keep out of the sight and reach of children.
Safety Information
Contraindicated in hypersensitivity to bortezomib, boron or mannitol, in acute diffuse infiltrative pulmonary and pericardial disease, and in pregnancy. Peripheral sensory and, less often, motor neuropathy is the dose-limiting toxicity and requires prompt dose modification. Cyclical thrombocytopenia, neutropenia and anaemia are expected and require a full blood count before each dose. Other important risks include hypotension, syncope, congestive cardiac failure, QT prolongation, gastrointestinal toxicity with risk of ileus, tumour lysis syndrome in high tumour burden, herpes zoster reactivation, hepatic impairment, posterior reversible encephalopathy syndrome and, rarely, thrombotic microangiopathy or progressive multifocal leukoencephalopathy. Antiviral prophylaxis is recommended. Effective contraception is required for men and women during and after treatment. Patients should be warned about dizziness, fatigue and blurred vision before driving.
Pharmacist Support
Every HubPharm order is reviewed by a licensed pharmacist before dispatch. You can reach our pharmacy team on WhatsApp at +234 705 050 5001, or through Afiya, our AI health companion, 24 hours a day in over 50 languages.
This information is provided for general education and does not replace the advice of a qualified healthcare professional. Always read the manufacturer’s leaflet supplied with your medicine.
